Fifty two children with insulin dependent diabetes mellitus were randomised to receive human isophane or lente insulin preparations in combination with soluble insulin in a double blind trial. Patients were seen every two months, and crossed over after four months of treatment. Control assessed by glycated haemoglobin was significantly lower in children on human isophane insulin, but fasting blood glucose and fructosamine concentrations and the number of episodes of hypoglycaemia were similar on both regimens. In five children on twice daily insulin regimens, insulin profiles throughout a 24 hour period demonstrated greater variability on lente compared with isophane insulin despite identically administered insulin doses. A questionnaire completed at the end of the study showed that two thirds of the children and/or their parents preferred the isophane insulin, and they gave perceived improvement of metabolic control as the major reason for their choice. Intermediate acting neutral crystalline protamine zinc insulin (isophane-also called neutral protamine Hagedorn insulin (NPH)) and insulin lente (zinc insulin) suspensions have been available for the last four decades. Both are frequently used in combination with short acting insulin in once or twice daily regimens in children with insulin dependent diabetes mellitus (IDDM). (table 1) . Thirteen children were on once daily and 39 were on twice daily insulin regimens. Forty two children were receiving pork lente or isophane insulin before commencing the study; the remaining children were receiving human insulin regimens.
Intermediate acting neutral crystalline protamine zinc insulin (isophane-also called neutral protamine Hagedorn insulin (NPH)) and insulin lente (zinc insulin) suspensions have been available for the last four decades. Both are frequently used in combination with short acting insulin in once or twice daily regimens in children with insulin dependent diabetes mellitus (IDDM). The consequences of mixing short (soluble) and intermediate acting insulins have only recently been thoroughly investigated.`-In adults with IDDM studies of the absorption, metabolic actions, and changes in plasma insulin concentrations have shown that lente insulin has a more protracted action than isophane insulin due to the loss of solubility of short acting insulin in the presence of excess zinc.3 ' There is some evidence that lente regimens may thus result in improved metabolic control in the early hours of the morning.5 6 Most trials that have formally compared isophane and lente insulins have been of low statistical power. 7 Furthermore, the recent change from pork to human insulin with its different absorption kinetics has again raised the question of whether these two insulins are interchangeable. 8 The only large trial comparing human isophane and lente insulins is that of Tunbridge et (table 1) . Thirteen children were on once daily and 39 were on twice daily insulin regimens. Forty two children were receiving pork lente or isophane insulin before commencing the study; the remaining children were receiving human insulin regimens.
TRIAL DESIGN
The trial was a double blind study with randomisation stratified for C peptide status and once/twice daily insulin regimen. Children were recruited one to two months before the beginning of the study and blood was drawn for C peptide estimation. The nature of the study was explained, techniques for syringe mixing and injection of insulin were reviewed and retaught as necessary, and children and parents were taught how to take blood samples onto filter paper for fasting blood glucose estimation. They were encouraged to achieve optimal glycaemic control before the beginning of the study.
Stratification and randomisation was performed by Novo Laboratories Ltd and the pharmacy at each hospital was provided with insulins identified by code, but not by name. At entry and every two months thereafter, fasting Hwnan isophane or lente insulin? A double blind crossover trial in insulin dependent diabetes mellitus At the end of the study, before breaking the code for insulin preparations, a questionnaire was given to each participant. Questions were categorised into two sections: the first related to perceptions about metabolic control and frequency of hypoglycaemic episodes and the second to feelings about general well being, energy levels, and irritability on each insulin regimen. Visual analogue scales were utilised in the questionnare and consisted of 10 cm lines. Each line was scored from 1 to 100 with 100 representing the extreme negative pole (for example, very grumpy, etc) and one representing the extreme positive pole. Children were also asked to indicate an overall preference for one or other regimen.
The protocol was reviewed and passed by ethical committees at both participating hospitals.
ANALYTICAL METHODS
Glycated haemoglobin was measured by the agar electrophoretic method (Corning) with an interassay coefficient of variation of 4-2%. The reference range for healthy children was 4-7 1 go/O. 10 Serum fructosamine was measured colorimetrically (Roche Diagnostics), the interassay coefficient of variation being 2-1% and normal range 2-6-3-3 mmol/l. Blood for fasting blood glucose estimation was taken onto filter paper impregnated with boric acid. After drying samples were sent to the Bristol Maternity Hospital for subsequent assay. After elution, glucose from the spots was measured by standard glucose oxidase method. Serum C peptide concentration was measured by radioimmunoassay, the lower limit of detection being 0 03 pmol/ml. For measurement of plasma free insulin 1-0 ml whole blood was added immediately to 0-6 ml of ice cold 25% polyethylene glycol (Sigma) and samples were stored at -4°C.1' The insulin assay used was a single antibody radioimmunoassay with charcoal separation.'2 Interassay coefficients of variation at 38-0, 49 5, 89-0, and 196-6 pmol/l were I-0, 7 The frequency of hypoglycaemic episodes was similar on both regimens: the number of grade 1 or 2 episodes was slightly increased on the lente based regimen, whereas the number of grade 3 or 4 episodes was greater on the isophane based regimen (table 2) .
Forty one children completed the questionnaires of whom 40 stated their preference for insulin regimen (table 4) . Twenty seven of 40 children (68%) stated that they preferred isophane to lente insulin, irrespective of the insulin regimen that they were taking at the time they completed the questionnaire (table 4) . Symptoms and signs of hyperglycaemia including polyuria, polydipsia, nausea, presence of urinary ketones, and high blood glucose values were reported twice as frequently on the lente compared with the isophane based regimen. In addition, 31/41 (76%) on lente compared with 18/41 (44%) on isophane insulin regimens perceived their blood glucose values to be very erratic (X2=8-9, p<0 03) and only 5/41 children (12%) perceived their blood glucose concentrations to be steady between 4-5 and 9 mmol/l on the lente insulin regimen compared with 18/41 children (44%) on the isophane insulin regimen. In all, 63% of those who preferred isophane insulin gave perceived improvement ofmetabolic control as their main reason for the preference. Significantly more problems with hypoglycaemic episodes were perceived on the lente based regimen (median difference in score + 12, interquartile range 0 to 38, p<0-01) and children reported lower levels of energy (median 0, interquartile range +6 to -17, p<0-01) on the lente than on the isophane insulin. Median irritability score was also higher on lente than isophane insulin (median score +0 5, interquartile range -7 to +26, p=007).
Discussion
This double blind crossover study in children with IDDM demonstrates lower glycated haemoglobin on an isophane/soluble insulin regimen compared with a lente/soluble insulin regimen. Although the differences in fructosamine and fasting blood glucose measurements between the regimens were small, values were lower with the isophane than with the lente based regimens and the high within individual variation in fasting blood glucose concentration renders this measure open to the possibility of a type 2 error (that is, failure to detect a significant difference when one exists) in a study of this size.
There have been few studies comparing human isophane and lente based insulin regimens in individuals with IDDM, and none have been performed in children. Our results contrast with those of Tunbridge et al in the only adult study with sufficient statistical power to effectively compare the two regimens who observed similar fasting blood glucose, variation in blood glucose and glycated haemoglobin on the two regimens.9 Corcoren and Yudkin3 and Oswald and Yudkin7 compared isophane and lente based regimens as well as pork and human insulin regimens in adults with IDDM, and found no significant differences; however, the numbers in the subsets studied were very small.
Eighty percent of the children in this study were previously on pork insulin. Equal numbers of children were randomly allocated to receive either lente or isophane insulin at the beginning of the study and no effect of regimen order was observed. It is unlikely that the change to human insulin affected the differences observed between isophane and lente insulins, although it is of interest to note that despite being in a trial, glycated haemoglobin rose on both regimens compared with baseline. In this study, 30% of children were positive for C peptide. When only children negative for C peptide were included in the analysis, however, the decrease in glycated haemoglobin on the isophane insulin regimen was similar to that obtained when all children were included. It is possible that the difference between our results and those of the adult studies are due to differences in factors such as insulin absorption kinetics and the presence ofa different hormonal environment in children compared with adults.
The increased prevalence of hyperglycaemic symptoms and the increased variability of blood glucose concentrations perceived by the children and parents who completed the retrospective questionnaire agree with the increased glycated haemoglobin and increased variation of free insulin and blood glucose concentrations observed on the lente based regimen. In contrast, although data from the retrospective questionnaire indicated that more problems with hypoglycaemia were perceived on the lente regimen, data collected prospectively throughout the trial showed no significant difference in the frequency of hypoglycaemic episodes between the two regimens. A possible explanation for this apparent discrepancy may be that in the questionnaire, parents and children were asked to express the degree to which hypoglycaemia was a problem on each insulin regimen using a visual analogue scale and not specifically about frequency of hypoglycaemic episodes. Thus other factors such as degree of warning before having a hypoglycaemic attack and timing of attacks may have influenced their response. More detailed study would be required to further investigate this question.
Finally, answers to subjective questions about well being, irritability, and energy levels, in addition to the fact that 67% of children chose to receive isophane insulin and only 12% chose to receive lente insulin after the end of the trial, indicate that isophane insulin is the more acceptable intermediate acting insulin for children.
We conclude that human isophane when used in a once or twice daily regimen together with soluble insulin results in better metabolic control, less diurnal variation in free insulin concentration, and is more acceptable to children than human lente insulin. We therefore suggest that this should be the intermediate insulin of first choice in the treatment of children with IDDM.
